CompletedPhase 4

A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension

United States

Plain-language summary

Evaluate the incidence of hyperemia in patients using bimatoprost and to determine if simple interventions reduce its incidence and to assess the value of detailed instruction in increasing patient compliance and willingness to continue bimatoprost therapy, despite the occurrence of hyperemia.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * · Male or female \> 18 years of age * No prior use of bimatoprost * Diagnosis of open-angle glaucoma or ocular hypertension * Ability to provide informed consent and likely to complete all study visits Exclusion Criteria: * · Known contraindication to bimatoprost * Uncontrolled systemic disease * Active ocular disease other than glaucoma or ocular hypertension * Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear solutions will be permitted) * History of intraocular surgery within the last 3 months

Trial details

NCT IDNCT00348062

SponsorInnovative Medical

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Glaucoma trials